Deep learning based low-activity PET reconstruction of [11C]PiB and [18F]FE-PE2I in neurodegenerative disorders

被引:11
|
作者
Daveau, Raphael Sura [1 ]
Law, Ian [1 ]
Henriksen, Otto Molby [1 ]
Hasselbalch, Steen Gregers [2 ]
Andersen, Ulrik Bjorn [1 ]
Anderberg, Lasse [1 ]
Hojgaard, Liselotte [1 ]
Andersen, Flemming Littrup [1 ]
Ladefoged, Claes Nohr [1 ]
机构
[1] Univ Copenhagen, Dept Clin Physiol & Nucl Med, Rigshosp, Copenhagen, Denmark
[2] Univ Copenhagen, Danish Dementia Res Ctr, Rigshosp, Copenhagen, Denmark
关键词
Parkinson's disease; F-18]FE-PE2I; Alzheimer's disease; C-11]PiB; Deep learning; PET denoising; DOPAMINE TRANSPORTER; DISEASE; CRITERIA;
D O I
10.1016/j.neuroimage.2022.119412
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Purpose: Positron Emission Tomography (PET) can support a diagnosis of neurodegenerative disorder by identifying disease-specific pathologies. Our aim was to investigate the feasibility of using activity reduction in clinical [F-18]FE-PE2I and [C-11]PiB PET/CT scans, simulating low injected activity or scanning time reduction, in combination with AI-assisted denoising. Methods: A total of 162 patients with clinically uncertain Alzheimer's disease underwent amyloid [C-11]PiB PET/CT and 509 patients referred for clinically uncertain Parkinson's disease underwent dopamine transporter (DAT) [F-18]FE-PE2I PET/CT. Simulated low-activity data were obtained by random sampling of 5% of the events from the list-mode file and a 5% time window extraction in the middle of the scan. A three-dimensional convolutional neural network (CNN) was trained to denoise the resulting PET images for each disease cohort. Results: Noise reduction of low-activity PET images was successful for both cohorts using 5% of the original activity with improvement in visual quality and all similarity metrics with respect to the ground-truth images. Clinically relevant metrics extracted from the low-activity images deviated < 2% compared to ground-truth values, which were not significantly changed when extracting the metrics from the denoised images. Conclusion: The presented models were based on the same network architecture and proved to be a robust tool for denoising brain PET images with two widely different tracer distributions (delocalized, ([C-11]PiB, and highly localized, [F-18]FE-PE2I). This broad and robust application makes the presented network a good choice for improving the quality of brain images to the level of the standard-activity images without degrading clinical metric extraction. This will allow for reduced dose or scan time in PET/CT to be implemented clinically.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Reliability of dopamine transporter PET measurements with [18F]FE-PE2I in patients with Parkinson’s disease
    Vera S. Kerstens
    Patrik Fazio
    Mathias Sundgren
    Granville J. Matheson
    Erika Franzén
    Christer Halldin
    Simon Cervenka
    Per Svenningsson
    Andrea Varrone
    EJNMMI Research, 10
  • [22] Reliability of dopamine transporter PET measurements with [18F]FE-PE2I in patients with Parkinson's disease
    Kerstens, Vera S.
    Fazio, Patrik
    Sundgren, Mathias
    Matheson, Granville J.
    Franzen, Erika
    Halldin, Christer
    Cervenka, Simon
    Svenningsson, Per
    Varrone, Andrea
    EJNMMI RESEARCH, 2020, 10 (01)
  • [23] Reliability and validity of visual analysis of [18F]FE-PE2I PET/CT in early Parkinsonian disease
    Bjerken, Sara Af
    Axelsson, Jan
    Larsson, Anne
    Flygare, Carolina
    Remes, Jussi
    Strandberg, Sara
    Eriksson, Linda
    Backstrom, David
    Jakobson Mo, Susanna
    NUCLEAR MEDICINE COMMUNICATIONS, 2023, 44 (05) : 397 - 406
  • [24] PET imaging of dopamine transporters with [18F]FE-PE2I: Effects of anti-Parkinsonian drugs
    Bang, Ji-In
    Jung, In Soon
    Song, Yoo Sung
    Park, Hyun Soo
    Moon, Byung Seok
    Lee, Byung Chul
    Kim, Sang Eun
    NUCLEAR MEDICINE AND BIOLOGY, 2016, 43 (02) : 158 - 164
  • [25] Fully Automated GMP-Compliant Synthesis of [18F]FE-PE2I
    Bratteby, Klas
    Denholt, Charlotte Lund
    Lehel, Szabolcs
    Petersen, Ida Nymann
    Madsen, Jacob
    Erlandsson, Maria
    Ohlsson, Tomas
    Herth, Matthias Manfred
    Gillings, Nic
    PHARMACEUTICALS, 2021, 14 (07)
  • [26] High yield GMP production of [18F]FE-PE2I, a radiotracer for in vivo PET imaging the dopamine transporter
    Moein, Mohammad Mahdi
    Dahl, Kenneth
    Meijer, Ellen
    Ferrat, Melodie
    Tegnebratt, Tetyana
    Saliba, Paul
    Norman, Fredrik
    Samen, Erik
    Steiger, Carsten
    Savitcheva, Irina
    Tran, Thuy
    NUCLEAR MEDICINE AND BIOLOGY, 2022, 108 : S132 - S133
  • [27] Identification of PET radiometabolites by cytochrome P450, UHPLC/Q-ToF-MS and fast radio-LC: applied to the PET radioligands [11C]flumazenil, [18F]FE-PE2I, and [11C]PBR28
    Amini, Nahid
    Nakao, Ryuji
    Schou, Magnus
    Halldin, Christer
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2013, 405 (04) : 1303 - 1310
  • [28] Identification of PET radiometabolites by cytochrome P450, UHPLC/Q-ToF-MS and fast radio-LC: applied to the PET radioligands [11C]flumazenil, [18F]FE-PE2I, and [11C]PBR28
    Nahid Amini
    Ryuji Nakao
    Magnus Schou
    Christer Halldin
    Analytical and Bioanalytical Chemistry, 2013, 405 : 1303 - 1310
  • [29] Amyloid, hypometabolism, and cognition in Alzheimer disease - An [11C]PIB and [18F]FDG PET study
    Edison, P.
    Archer, H. A.
    Hinz, R.
    Hammers, A.
    Pavese, N.
    Tai, Y. F.
    Hotton, G.
    Cutler, D.
    Fox, N.
    Kennedy, A.
    Rossor, M.
    Brooks, D. J.
    NEUROLOGY, 2007, 68 (07) : 501 - 508
  • [30] An efficient one-step radiosynthesis of [18F]FE-PE2I, a PET radioligand for imaging of dopamine transporters
    Stepanov, Vladimir
    Krasikova, Raisa
    Raus, Liina
    Loog, Olavi
    Hiltunen, Jukka
    Halldin, Christer
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2012, 55 (06): : 206 - 210